4//SEC Filing
Prentice Anthony 4
Accession 0001209191-23-031512
CIK 0001818331other
Filed
May 21, 8:00 PM ET
Accepted
May 22, 5:03 PM ET
Size
10.0 KB
Accession
0001209191-23-031512
Insider Transaction Report
Form 4
Prentice Anthony
Chief Product Officer
Transactions
- Exercise/Conversion
Class A Common Stock
2022-07-01+4,576→ 14,436 total - Sale
Class A Common Stock
2022-07-05$1.32/sh−1,828$2,411→ 12,608 total - Exercise/Conversion
Restricted Stock Unit
2022-07-01−4,576→ 68,642 total→ Class A Common Stock (4,576 underlying)
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.215 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]6.25% of the total shares underlying the restricted stock units vest in quarterly installments beginning on July 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Documents
Issuer
GeneDx Holdings Corp.
CIK 0001818331
Entity typeother
Related Parties
1- filerCIK 0001873901
Filing Metadata
- Form type
- 4
- Filed
- May 21, 8:00 PM ET
- Accepted
- May 22, 5:03 PM ET
- Size
- 10.0 KB